BNET Industries

Pharmaceutical Product Development Inc.

(PPDI) is in the Health Care Industry

Market Cap:$2.6B
Last Fiscal Year Sales:$1.5B
  • Public
  • US
Dow Jones Description

PPD supports the drug industry in improving health. Founded in 1985 and headquartered in Wilmington, NC, Pharmaceutical Product Development, Inc. (NASDAQ: PPDI) provides services to the pharmaceutical industry. The company operates in two segments: Discovery Sciences and Development. It offers discovery and development services, laboratory services, data management, regulatory consulting, test subject recruiting, and more. Customers include pharmaceutical, biotechnology, and medical firms and government organizations. It operates in North America, South America, and Europe. The company has annual revenue of about $1 billion and employs more than 10,400 people. In 2005, Standard & Poor's named PPD to its MidCap 400, reflecting the market's recognition of it's growth and value. In February 2005, the company acquired substantially all of the assets of SurroMed, Inc.'s biomarker business.

Number of Employees 10,500
Contact Information

929 North Front Street

Wilmington, North Carolina 28401-3331

www.ppdi.com

(910) 251-0081

NAICS Code Research and Development in the Physical, Engineering, and Life Sciences: 54171

Recent Events

  • PPD Selected as Exclusive Partner by DiabetesAmerica

    12/17/09 - Joint Venture / Alliance - View Story

  • PPD Launches Global Biostatistics Technology Infrastructure

    12/07/09 - Product Announcement - View Story

  • PPD completes $77 million acquisition of BioDuro

    12/01/09 - Merger / Acquisition - View Story

  • PPD spends $77 million for China expansion

    11/30/09 - Merger / Acquisition - View Story

  • PPD, Inc. PPDI Announces Agreement with Janssen Pharmaceutica to Commercialize 2 Phase II-Ready Therapeutic Compounds

    11/16/09 - Joint Venture / Alliance - View Story

  • PPD Declares Fourth Quarter Dividend

    11/11/09 - Stock Split / Dividend - View Story

  • Pharmaceutical Product Development PPDI Dow

    10/29/09 - Bond / Stock Rating - View Story

  • Pharmaceutical Product Development PPDI Downgraded By Wells Fargo

    10/29/09 - Bond / Stock Rating - View Story

  • PPD buys CRO, creates spin-offs and invests $100M in Celtic

    10/28/09 - Planned Site Openings - View Story

  • BRIEF-PPD to invest $100 mln in Celtic Therapeutics Holdings

    10/27/09 - New Investment - View Story

  • PPD Announces Plans to Spin off Compound Partnering Business

    10/27/09 - Licensing / Contract - View Story

  • PPD makes major moves; shares slide

    10/28/09 - New Investment - View Story

  • Pharmaceutical Product Development PPDI Reports Inline Q3 EPS of $0.32

    10/27/09 - Financial Announcement - View Story

  • PPD expands presence in China with acquisition

    11/06/09 - Merger / Acquisition - View Story

  • BRIEF-RESEARCH ALERT-Jefferies raises targets on PPD, 2 others

    10/13/09 - Bond / Stock Rating - View Story

  • Ahead of the Bell: Pharma Product Development Inc.

    10/12/09 - Bond / Stock Rating - View Story

  • PPD Declares Third Quarter Dividend

    8/18/09 - Stock Split / Dividend - View Story

  • Pharmaceutical Product Development shares plunge 10%

    7/22/09 - Bond / Stock Rating - View Story

  • PPD Q2 Earnings At $0.49 Including Gain On Piedmont Research Center Sale - Update

    7/21/09 - Financial Announcement - View Story

  • PPD leaves research campus

    6/25/09 - Mgmt. Change Entering - CEO - View Story

News & Analysis

finance and pharmaceutical product development inc. - All News and Analysis

advertisement
     PPDI $22.48 +0.92 (4.27% )
Intraday | 3 Month | 6 Month | 1 Year
Average Volume 1,345,630
Shares Outstanding 118.16M
Market Cap 2.7B
Year High 29.53
Year Low 17.97
Earnings Per Share 1.42
P/E Ratio 15.83
Dividend 0.60
Yield 2.67
IndustryTop Rated

Brought to you by CBS MoneyWatch.com

advertisement
Click Here
Presented by American Express